Early research suggests psilocybin, the active compound in magic mushrooms, can reduce several types of chronic pain. The evidence is strongest for cluster headaches and migraines, with growing data on fibromyalgia, neuropathic pain, and cancer-related pain. Most of this research is still in early stages, with small sample sizes and limited clinical trials in humans, but the results so far are promising enough to fuel a wave of larger studies.
How Psilocybin Affects Pain in the Brain
Chronic pain isn’t just about signals from an injury site. Over time, the brain itself changes, with certain regions becoming hyperactive and amplifying pain signals even after the original cause has healed or stabilized. Psilocybin appears to target this central amplification directly.
In a 2025 study published in Nature Neuroscience, researchers gave mice with chronic nerve injury and inflammatory pain a single dose of psilocybin. Within 24 hours, heightened pain sensitivity reversed, and the effect lasted at least 12 days. The key finding was where this happened: the anterior cingulate cortex, a brain region involved in processing the emotional and sensory dimensions of pain. Using calcium imaging, researchers observed that psilocybin normalized the hyperactivity of neurons in this area that had been firing excessively due to chronic pain. Alongside pain relief, anxiety and depression-like behaviors also improved in both male and female mice.
This dual effect matters because chronic pain and mood disorders reinforce each other. Pain makes people anxious and depressed, which makes pain feel worse. Psilocybin appears to interrupt both sides of that cycle simultaneously. Researchers believe this happens through the restructuring of maladaptive neural circuits, essentially helping the brain “unlearn” patterns of pain signaling that have become self-sustaining. Unlike standard painkillers that wear off in hours, psilocybin’s effects on neural plasticity may explain why a single dose can produce relief lasting days or weeks.
Cluster Headaches and Migraines
The most developed body of evidence for psilocybin and pain involves headache disorders, particularly cluster headaches, which are sometimes called “suicide headaches” because of their severity. A systematic review across six studies found that participants consistently reported improvements in headache frequency, intensity, and duration. Two studies showed decreased attack frequency, three reported reduced intensity, and one found shorter headache episodes.
The most striking result involved remission periods. Among people who took psilocybin during a remission phase (the gap between headache cycles), 91% experienced an extension of that pain-free window. This is significant for cluster headache sufferers, who often dread the return of their next cycle and have few effective preventive options. Full doses appeared to work better than microdoses: macrodosers experienced 12.3% more pain reduction three days after dosing compared to microdosers. Three of the six studies achieved statistical significance, which is notable given the small sample sizes typical of psychedelic research.
Fibromyalgia
Fibromyalgia, a condition marked by widespread pain, fatigue, and sleep problems, is notoriously difficult to treat. A pilot clinical trial (NCT05128162) tested psilocybin-assisted therapy in five adults with fibromyalgia and found clinically meaningful improvements one month after the second dose. Pain severity dropped substantially, with a large effect size of 2.1 on the Cohen’s d scale, meaning the improvement was well beyond what you’d expect from chance or placebo. Pain interference with daily life and sleep disturbance also improved significantly.
Three of the five participants rated their symptoms as “much improved” or “very much improved” on a standard patient rating scale, while the remaining two reported minimal improvement. The treatment was well tolerated: blood pressure and heart rate rose temporarily during dosing sessions but returned to normal, and four participants had transient headaches afterward. No serious adverse events occurred. At least three larger, controlled trials for fibromyalgia are now underway, including double-blind, placebo-controlled designs that will provide more definitive answers.
Neuropathic and Phantom Limb Pain
Neuropathic pain, caused by nerve damage from conditions like chemotherapy, diabetes, or amputation, responds poorly to conventional painkillers. Animal research shows psilocybin can reverse pain behaviors in both chemotherapy-induced nerve damage and inflammatory pain models, with effects lasting well beyond the drug’s presence in the body. This persistence sets psilocybin apart from other psychedelics, suggesting it triggers lasting changes in how peripheral and central nerves process pain signals rather than simply masking symptoms.
Clinical case reports in people with neuropathic pain have found that even low, sub-psychedelic doses produced purely analgesic effects, meaning pain relief occurred without a psychedelic experience. This is a meaningful distinction. It suggests that for some types of pain, the therapeutic benefit doesn’t require a full “trip,” which could make treatment more accessible and practical. Phantom limb pain, where amputees feel pain in a limb that no longer exists, is also being explored in clinical trials, though published results from those studies are still limited.
Microdosing vs. Full Doses
The question of dose matters. Full doses of psilocybin, those that produce a noticeable psychedelic experience, appear to deliver stronger pain relief than microdoses. The headache research showed a clear advantage for macrodosers over microdosers in pain reduction. And the fibromyalgia trial used full therapeutic doses paired with psychological support, not microdoses.
That said, the neuropathic pain case reports showing analgesic effects at sub-psychedelic doses suggest microdosing isn’t without value for certain conditions. The picture is incomplete because no large controlled trial has directly compared microdosing to full dosing for pain. For now, the stronger evidence favors full doses administered in a supervised setting.
Risks and Side Effects
Psilocybin is not risk-free. Common side effects include temporary increases in blood pressure and heart rate, headache, nausea, dizziness, fatigue, and anxiety during the experience. Some people report paranoia or disturbing hallucinations, particularly at higher doses or in unsupervised settings.
Microdosing carries its own set of concerns. Reported downsides include insomnia, increased anxiety and depression, gastrointestinal discomfort, poor focus, and disrupted senses. These effects are generally mild but worth knowing about, especially for people who assume smaller doses are inherently safe.
Psilocybin is not safe for people with psychotic conditions like schizophrenia or schizoaffective disorder, or severe forms of bipolar disorder and borderline personality disorder. The compound can trigger or worsen psychotic episodes in these populations. For people with chronic pain who also take serotonin-affecting medications like certain antidepressants, there are potential drug interactions that need careful consideration. Psilocybin remains a Schedule I substance federally in the United States, though some states and cities have moved toward decriminalization or regulated therapeutic access.
Where the Evidence Stands
The animal research is robust and consistent: a single dose of psilocybin can reverse established chronic pain states through measurable changes in brain activity. The human evidence is earlier-stage but points in the same direction, with the strongest clinical data in headache disorders and a promising pilot in fibromyalgia. Multiple controlled trials are now recruiting or underway for fibromyalgia, neuropathic pain, and other chronic pain conditions.
What makes psilocybin unusual compared to existing pain treatments is the duration of effect from a single or small number of doses, the simultaneous improvement in pain and mood, and the potential to address pain at the level of brain circuitry rather than simply blocking pain signals. The gap between current evidence and clinical availability remains wide, but the early data explains why both researchers and patients are paying close attention.